Related Experiment Videos
The effect of bromhexine on the kidney lesions in NZB-NZW-F1 mice
Abstract:
The NZB-NZW-F1 mice develop a clinical picture resembling SLE and an exocrinopathy resembling Sjögren's syndrome. Three groups of hybrids were treated from their 20th week of age for 10, 17 and 20 weeks (groups 1, 2, 3) with Bromhexine in two different concentrations--6 & 60 mg/kg and placebo. NMRJ mice treated with placebo acted as healthy controls. After the treatment the kidneys were examined by light microscopy. The kidneys exhibited lupus-like lesions. Animals treated with 60 mg/kg Bromhexine for 17 weeks had a significantly lower degree of changes than had the other hybrids.
Insights
Bromhexine treatment in lupus-prone mice (NZB-NZW-F1) reduced kidney damage. A 60 mg/kg dose for 17 weeks showed significant benefits against lupus-like kidney lesions in this SLE model.
Area of Science:
- Immunology
- Nephrology
- Pharmacology
Background:
- NZB-NZW-F1 mice spontaneously develop a lupus-like autoimmune disease.
- These mice also exhibit exocrinopathy, mimicking Sjögren's syndrome.
- Systemic lupus erythematosus (SLE) and Sjögren's syndrome are autoimmune disorders with significant morbidity.
Purpose of the Study:
- To investigate the therapeutic potential of Bromhexine in a murine model of SLE and Sjögren's syndrome.
- To evaluate the effect of Bromhexine on lupus-like kidney pathology in NZB-NZW-F1 mice.
- To determine dose- and duration-dependent effects of Bromhexine on autoimmune manifestations.
Main Methods:
- NZB-NZW-F1 mice were treated with Bromhexine (6 & 60 mg/kg) or placebo from 20 weeks of age for 10, 17, or 20 weeks.
- Kidney tissues were analyzed using light microscopy to assess lupus-like lesions.
- NMRJ mice served as healthy controls.
Main Results:
- The kidneys of untreated and placebo-treated mice showed lupus-like lesions.
- Bromhexine treatment, particularly at 60 mg/kg for 17 weeks, significantly reduced the severity of kidney damage compared to other treatment groups.
- A dose-dependent and duration-dependent effect was observed, with higher doses and longer treatment periods showing greater impact.
Conclusions:
- Bromhexine demonstrates a protective effect on kidneys in a murine model of SLE.
- The findings suggest Bromhexine may be a potential therapeutic agent for managing lupus nephritis.
- Further research is warranted to explore the mechanisms underlying Bromhexine's renoprotective effects in autoimmune diseases.